1. Introduction {#sec1}
===============

Vitiligo is an idiopathic, acquired pigmentation disorder of skin and/or mucosa, with clinical manifestations of porcelain white patches. It is considered to be a multifactorial and polygenic disease caused by the destruction of melanocytes \[[@B1]\]. Amongst others, oxidative stress is considered to be one of the causative factors in the pathogenesis of vitiligo \[[@B2]\].

Glutathione peroxidase (GPx) is the general name of an enzyme family with peroxidase activity. It protects cells from oxidative damage through decreasing lipid hydroperoxides to their corresponding alcohols or reducing free hydrogen peroxide to water \[[@B3]\]. In vitiligo, many researches about this antioxidant marker have been sought, but the conclusions were conflicting. Some researchers reported elevated level, whereas others showed no change or reduced level. Due to the inconsistent results, we do the meta-analysis to clarify the GPx level in vitiligo patients.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

The PubMed, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wan Fang Med Online were searched by two independent investigators using the search terms ("vitiligo") and ("glutathione peroxidase" or "GPx" or "GSH-Px" or "oxidant" or "antioxidant"). Additional potential relevant articles were further retrieved through a manual search of references from original reports. The research dated from the earliest time to December 2015.

2.2. Eligibility Criteria and Excluded Studies {#sec2.2}
----------------------------------------------

We sought existing studies published in English or Chinese. Articles were included in this meta-analysis if (1) the case group consisted of vitiligo patients and the control group included healthy individuals and (2) the outcome measures reported quantitative GPx level (mean ± standard deviation). After reading the title and abstract, we excluded a study if it (1) was an animal or in vitro experiment, (2) was a case report or a review, and (3) consisted of duplicate data with other study. All studies were deliberately reviewed by two investigators to decide whether to be included.

2.3. Data Extraction {#sec2.3}
--------------------

Two investigators independently screened studies for eligible articles. The following items including the first author, year of publication, nation, sample size, sources, test method of GPx, GPx estimated value, unit, type, and stage of vitiligo were extracted. If there were discrepancies, they would reach a consensus through discussion and reexamination or seeking help to a third investigator.

2.4. Quality Assessment {#sec2.4}
-----------------------

To estimate the quality of included studies, the Newcastle-Ottawa Scale (NOS) criteria were used by two investigators independently \[[@B4]\]. The NOS criteria were scored based on three aspects: (1) subject selection, 0\~4, (2) comparability of subject, 0\~2, and (3) clinical outcome, 0\~3. Total NOS scores range from 0 (the lowest) to 9 (the highest). Any discrepancy between the two investigators on NOS scores of the enrolled studies was resolved by discussion or consultation with a third investigator.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The standard mean difference (SMD) for the effect and corresponding 95% CIs were calculated from the original data of the appropriate studies in fixed effects model (Mantel-Haenszel method) or random-effects model (DerSimonian and Laird method). The random-effects model was applied when heterogeneity existed among studies, while the fixed effects model was applied when there was no statistical heterogeneity. In order to test for comparability, heterogeneity across the included studies was evaluated by Cochran *Q* test and *I* ^2^ test \[[@B5]\]. Subgroup meta-analyses were conducted according to race (Caucasian versus Asian), stage (active or stable), type (segmental or nonsegmental), or source of sample. The funnel plot was constructed to assess the effect of publication bias on the validity of the estimates. The symmetry of the funnel plot was further evaluated by Egger\'s linear regression test \[[@B6]\]. All tests were two-sided, and a *p*value of \< 0.05 was regarded as statistically significant. Stata version 11.0 software (StataCorp., College Station, TX, USA) was performed for statistical analysis.

3. Results {#sec3}
==========

3.1. Eligible Studies {#sec3.1}
---------------------

We identified 215 studies according to search strategy as shown in [Figure 1](#fig1){ref-type="fig"}. After carefully reviewing and screening, 23 articles \[[@B3], [@B7]--[@B28]\] were finally included in the meta-analysis. The characteristic and methodological qualities of these studies were shown in [Table 1](#tab1){ref-type="table"}. The overall study quality ranged from 5 to 7 stars. Of the 23 studies, the sample resource of 20 studies was either serum, plasma, erythrocyte, blood, skin, or blister fluid, and other 3 studies, respectively, tested the GPx level in two sample sources. So the total number of comparisons used in the meta-analysis was 26. The race of all included studies was Caucasian or Asian population. The levels of GPx stratified by sample sources and races were listed in [Table 2](#tab2){ref-type="table"}.

3.2. The Levels of GPx in Vitiligo Patients and Healthy Controls {#sec3.2}
----------------------------------------------------------------

Random-effects model was applied to the pooled meta-analysis, as statistical heterogeneity existed among studies (*χ* ^2^ = 741.66, *p* = 0.000, and *I* ^2^ = 96.6%). The results indicated that patients with vitiligo had equivalent levels of GPx with the healthy controls (SMD = −0.47, 95% CI: −1.03 to 0.08, and *p* = 0.095) ([Figure 2](#fig2){ref-type="fig"}).

Further subgroup analysis stratified by sample sources indicated that vitiligo patients had higher GPx levels than controls in skin (SMD = 1.49, 95% CI: 0.06 to 2.91, and *p* = 0.041) and lower GPx levels than controls in blood (SMD = −1.06, 95% CI: −2.06 to −0.06, and *p* = 0.038). No difference was seen in the source of serum (SMD = −1.24, 95% CI: −2.79 to 0.31, and *p* = 0.117), plasma (SMD = −0.05, 95% CI: −1.43 to 1.34, and *p* = 0.948), erythrocyte (SMD = −0.97, 95% CI: −1.94 to 0.00, and *p* = 0.050), or blister fluid (SMD = −0.29, 95% CI: −1.56 to 0.98, and *p* = 0.657) ([Figure 3(a)](#fig3){ref-type="fig"}). The analysis stratified by race indicated that vitiligo patients in Asian populations had lower GPx levels than controls (SMD = −0.47, 95% CI: −1.08 to 0.14, and *p* = 0.001), but no difference was shown in Caucasian populations (SMD = 0.259, 95% CI: −0.28 to 0.80, and *p* = 0.346) ([Figure 3(b)](#fig3){ref-type="fig"}). Five articles were included in the subgroup analyses stratified by stage and sample source of serum/plasma ([Table 3](#tab3){ref-type="table"}). The results indicated that the vitiligo patients at either stable stage or active stage had lower GPx levels in serum/plasma compared to controls (stable: SMD = −2.01, 95% CI: −3.52 to −0.49, and *p* = 0.009; active: SMD = −2.34, 95% CI: −4.07 to −0.61, and *p* = 0.008) (Figures [4(a)](#fig4){ref-type="fig"} and [4(b)](#fig4){ref-type="fig"}). No significant difference was observed between stable stage and active stage (SMD = 0.50, 95% CI: −0.02 to 1.01, and *p* = 0.058). Three articles were included in the subgroup analyses stratified by vitiligo type ([Table 4](#tab4){ref-type="table"}). Segmental vitiligo patients had lower GPx levels compared to controls (SMD = −3.59, 95% CI: −6.38 to −0.80, and *p* = 0.012). No significant difference was observed between nonsegmental vitiligo patients and controls (SMD = −2.81, 95% CI: −5.71 to 0.10, and *p* = 0.058) or between segmental and nonsegmental vitiligo patients (SMD = −0.18, 95% CI: −0.47 to 0.11, and *p* = 0.230).

3.3. Metaregression and Sensitivity Analyses {#sec3.3}
--------------------------------------------

Univariate and multivariate metaregression analyses were used to explore possible sources of heterogeneity. The results showed that race could be the major source of heterogeneity ([Table 5](#tab5){ref-type="table"}). The results of sensitivity analysis suggested that no individual studies significantly affected the pooled results, indicating a statistically robust result ([Figure 5](#fig5){ref-type="fig"}).

3.4. Publication Bias {#sec3.4}
---------------------

We used Egger\'s test to estimate the possibility of publication bias. The results showed that there was no obvious evidence of publication bias (*t* = 0.32, *p* = 0.754).

4. Discussion {#sec4}
=============

Oxidative stress inducing vitiligo is based on the fact that some intermediates such as 3,4-dihydroxyphenylalanine (dopa), dopachrome, and 5,6-dihydroxyindole are created during melanin biosynthesis \[[@B29]\]. The final result of these changes results in the continuous increase of hydrogen peroxide (H~2~O~2~), which restrains the antioxidative enzyme activity leading to the destruction of melanocytes \[[@B30]\]. Therefore, antioxidants are important to nullify the harmful radical-mediated reactions. GPx is a group of antioxidative markers against free radicals by detoxification and has been considered to be involved in the pathogenesis of many skin diseases \[[@B31]--[@B33]\]. Our meta-analysis investigated whether GPx is involved in the development of vitiligo. The results of included articles involving 26 comparisons on the relationship of GPx and vitiligo were controversial; that is, respective 50%, 31%, and 19% comparisons showed lower, equal, and higher levels in vitiligo samples. The difference may relate to the variations in the population race, disease type, activity, duration, sample sources, or detection method.

Till now, no meta-analysis has reported the association between the GPx level and vitiligo. The pooled meta-analysis results of all the comparisons indicated that the GPx levels in vitiligo patients were similar to healthy controls. As statistical heterogeneity existed among studies, we did further subgroup analysis. The results indicated a significant relationship between low GPx level and vitiligo incidence.

Our subgroup analysis showed that Asian vitiligo patients showed lower levels of GPx than the controls, but no difference was shown between Caucasian populations and healthy controls. The metaregression results, which showed that race could be the major source of heterogeneity of pooled meta-analysis, supported the above subgroup analysis results. The majority of previous studies have used serum or plasma to measure oxidant or antioxidant levels. In the present meta-analysis, whatever stable vitiligo patients or active vitiligo patients had lower serum/plasma levels of GPx than the controls. The patients with segmental type also had decreased GPx levels comparing to healthy controls. These results suggested that low GPx level may contribute to the pathogenesis of vitiligo in Asian population, unlike Caucasian population. The low level in serum/plasma was associated with vitiligo incidence, at whatever active stage or stable stage, especially in segmental vitiligo. Oxidative stress induced accumulation of toxic-free radicals may have a pathophysiologic role in the initiation and progression of vitiligo \[[@B2]\]. Reactive oxygen species (ROS) are scavenged by antioxidant defence mechanisms. Depletion of the endogenous antioxidants including GPx can overwhelm antioxidant defence mechanisms, resulting in oxidative stress medicated vitiligo. Besides, allelic variants in GPx gene may be associated with low levels of GPx activity \[[@B34], [@B35]\]. One previous study indicated that GPx polymorphism may contribute to the reduced GPx activity and the prevalence of vitiligo in Gujarat population \[[@B36]\].

In conclusion, this meta-analysis showed a significant association between low GPx level and vitiligo for Asian population or segmental patients. The low level in serum/plasma was associated with vitiligo incidence, at whatever active or stable stage. Nonetheless, the conclusion could not be completely confirmed as there are some limitations. The limited number, small sample sizes of studies, and methodological diversities may weaken the statistical power. More large-sample studies of higher quality should be done to verify the conclusions.
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###### 

Characteristic and methodological qualities of included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                           Nation    Number of participants\   Source          Test method   Unit           Type                      Stage            NOS score
                                            (patients/controls)                                                                                               
  ------------------------------- --------- ------------------------- --------------- ------------- -------------- ------------------------- ---------------- -----------
  Zedan et al. \[[@B3]\]          Egypt     60/30                     Serum           1             U/L            Generalized, localized    Stable, active   7

  Barikbin et al. \[[@B7]\]       Iran      60/45                     Serum           2             U/L            Vulgaris                  Active           5

  Ozturk et al. \[[@B8]\]         Turkey    30/30                     Serum           4             U/mg protein   Generalized               Stable           5

  Zhao et al. \[[@B9]\]           China     40/10                     Serum           ---           ---            ---                       Stable, active   5

  Chen et al. \[[@B10]\]          China     132/50                    Serum           3             U/L            Vulgaris, segmental       Stable, active   5

  Ma et al. \[[@B11]\]            China     69/44                     Serum           3             U/L            Vulgaris, segmental       ---              5

  Wang and Xu \[[@B12]\]          China     34/30                     Serum           1             U/mg protein   ---                       ---              7

  Batçioğlu et al. \[[@B13]\]     Turkey    37/15                     Plasma          4             U/mg protein   ---                       ---              7

  Hazneci et al. \[[@B14]\]       Turkey    23/25                     Plasma          5             U/mg protein   Vulgaris                  Active           6

  Zeng et al. \[[@B15]\]          China     50/50                     Plasma          ---           U/L            ---                       Stable, active   5

  Liu et al. \[[@B16]\]           China     60/40                     Plasma          3             U              ---                       Stable, active   7

  Karsli et al. \[[@B17]\]        Turkey    24/27                     Erythrocyte     1             U/g Hb         Generalized               ---              7

  Ines et al. \[[@B18]\]          Tunisia   36/40                     Erythrocyte     6             U/g protein    ---                       Stable, active   5

  Hazneci et al. \[[@B14]\]       Turkey    23/25                     Erythrocyte     1             U/g Hb         Vulgaris                  Active           6

  Yildirim et al. \[[@B19]\]      Turkey    24/20                     Erythrocyte     1             U/g Hb         Generalized               Stable           5

  Jain et al. \[[@B20]\]          India     75/25                     Blood           1             U/L            ---                       Stable, active   5

  Jalel and Hamdaoui \[[@B21]\]   Tunisia   60/62                     Blood           1             U/L            ---                       ---              5

  Shajil and Begum \[[@B22]\]     India     124/126                   Blood           7             U/mg protein   Segmental, nonsegmental   ---              5

  Ha \[[@B23]\]                   China     35/31                     Blood           ---           U              ---                       Active           5

  Batçioğlu et al. \[[@B13]\]     Turkey    33/15                     Skin            4             U/mg protein   ---                       ---              7

  Dammak et al. \[[@B24]\]        Tunisia   20/20                     Skin            1             U/mg protein   Vulgaris                  Stable, active   7

  Yildirim et al. \[[@B25]\]      Turkey    25/25                     Skin            1             U/mg protein   Generalized               Stable           5

  Passi et al. \[[@B26]\]         Italy     15/15                     Skin            1             U/mg protein   ---                       Active           7

  Zeng et al. \[[@B15]\]          China     50/50                     Blister fluid   ---           U/L            ---                       Stable, active   5

  Li et al. \[[@B27]\]            China     24/10                     Blister fluid   3             U              ---                       Stable, active   7

  Xu et al. \[[@B28]\]            China     19 (self control)         Blister fluid   3             U              ---                       Stable           7
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. NOS, Newcastle-Ottawa Scale; 1: Paglia and Valentine\'s method (1967); 2: flameless atomic absorption (graphite furnace) method; 3: DTNB colorimetry; 4: Lawrence and Burk\'s method (1976); 5: Najwa\'s method (1990); 6: Paglia\'s method (2002); 7: Beutler\'s method (1989).

###### 

The level of glutathione peroxidase of vitiligo patients stratified by sample sources and races (mean ± SD).

  Study                           Race        Unit           Case                  Control               Source
  ------------------------------- ----------- -------------- --------------------- --------------------- ---------------
  Zedan et al. \[[@B3]\]          Caucasian   U/L            0.29 ± 0.14           0.47 ± 0.13           Serum
  Barikbin et al. \[[@B7]\]       Caucasian   U/L            191.300 ± 14.95       183.288 ± 13.42       Serum
  Ozturk et al. \[[@B8]\]         Caucasian   U/mg protein   0.550 ± 0.077         0.439 ± 0.075         Serum
  Zhao et al. \[[@B9]\]           Asian       ---            292.21 ± 127.42       280.88 ± 47.25        Serum
  Chen et al. \[[@B10]\]          Asian       U/L            140030 ± 15260        216440 ± 8610         Serum
  Ma et al. \[[@B11]\]            Asian       U/L            102.08 ± 19.32        154.76 ± 27.06        Serum
  Wang and Xu \[[@B12]\]          Asian       U/mg protein   0.000981 ± 0.000257   0.001722 ± 0.000602   Serum
  Batçioğlu et al. \[[@B13]\]     Caucasian   U/mg protein   381.57 ± 12.67        346.13 ± 21.90        Plasma
  Hazneci et al. \[[@B14]\]       Caucasian   U/mg protein   0.205 ± 0.192         0.171 ± 0.012         Plasma
  Zeng et al. \[[@B15]\]          Asian       U/L            98.44 ± 14.23         114.33 ± 10.41        Plasma
  Liu et al. \[[@B16]\]           Asian       U              96.40 ± 15.78         115.14 ± 12.20        Plasma
  Karsli et al. \[[@B17]\]        Caucasian   U/g Hb         13.71 ± 3.85          18.87 ± 4.42          Erythrocyte
  Ines et al. \[[@B18]\]          Caucasian   U/g protein    1160 ± 440            1890 ± 820            Erythrocyte
  Hazneci et al. \[[@B14]\]       Caucasian   U/g Hb         97836.86 ± 17947.61   90257.83 ± 15776.65   Erythrocyte
  Yildirim et al. \[[@B19]\]      Caucasian   U/g Hb         31.34 ± 14.3          101.57 ± 48.4         Erythrocyte
  Jain et al. \[[@B20]\]          Caucasian   U/L            4004 ± 482.34         3945 ± 552            Blood
  Jalel and Hamdaoui \[[@B21]\]   Caucasian   U/L            42 ± 23.24            49 ± 14.17            Blood
  Shajil and Begum \[[@B22]\]     Caucasian   U/mg protein   944.55 ± 160.92       1036.8 ± 269.6        Blood
  Ha \[[@B23]\]                   Asian       U              128.18 ± 18.35        206.14 ± 21.50        Blood
  Batçioğlu et al. \[[@B13]\]     Caucasian   U/mg protein   170.98 ± 12.35        121.91 ± 16.03        Skin
  Dammak et al. \[[@B24]\]        Caucasian   U/mg protein   2.73 ± 0.81           1.78 ± 0.43           Skin
  Yildirim et al. \[[@B25]\]      Caucasian   U/mg protein   3.72 ± 2.09           1.58 ± 0.48           Skin
  Passi et al. \[[@B26]\]         Caucasian   U/mg protein   0.43 ± 0.10           0.47 ± 0.08           Skin
  Zeng et al. \[[@B15]\]          Asian       U/L            86.53 ± 7.83          98.26 ± 8.87          Blister fluid
  Li et al. \[[@B27]\]            Asian       U              148.73 ± 51.91        115.01 ± 29.57        Blister fluid
  Xu et al. \[[@B28]\]            Asian       U              90.67 ± 63.07         96.76 ± 63.51         Blister fluid

###### 

The level of glutathione peroxidase of vitiligo patients stratified by stage and healthy controls (mean ± SD).

  Study                     Unit           Case                         Control                      Source                      
  ------------------------- -------------- ---------------------------- ---------------------------- --------------------------- ---------------
  Zedan et al. \[[@B3]\]    U/L            0.27 ± 0.17 (*n* = 9)        0.29 ± 0.14 (*n* = 48)       0.47 ± 0.13 (*n* = 30)      Serum
  Zhao et al. \[[@B9]\]     ---            346.93 ± 156.84 (*n* = 14)   262.75 ± 103.54 (*n* = 26)   280.88 ± 47.25 (*n* = 10)   Serum
  Chen et al. \[[@B10]\]    U/L            139120 ± 11760 (*n* = 12)    140940 ± 13210 (*n* = 120)   216440 ± 8610 (*n* = 50)    Serum
  Zeng et al. \[[@B15]\]    U/L            104.39 ± 11.49 (*n* = 30)    88.74 ± 18.23 (*n* = 20)     114.33 ± 10.41 (*n* = 50)   Plasma
  Liu et al. \[[@B16]\]     U              103.08 ± 14.95 (*n* = 30)    89.72 ± 13.80 (*n* = 30)     115.14 ± 12.20 (*n* = 40)   Plasma
  Ines et al. \[[@B18]\]    U/g protein    1250 ± 470 (*n* = 18)        1060 ± 380 (*n* = 18)        1890 ± 820 (*n* = 40)       Erythrocyte
  Jain et al. \[[@B20]\]    U/L            3990 ± 459 (*n* = 25)        4011 ± 498 (*n* = 50)        3945 ± 552 (*n* = 25)       Blood
  Ha \[[@B23]\]             U/mg protein   2.48 ± 0.81 (*n* = 10)       2.98 ± 0.77 (*n* = 10)       1.78 ± 0.43 (*n* = 20)      Skin
  Zeng et al. \[[@B15]\]    U/L            95.33 ± 9.37 (*n* = 30)      80.69 ± 10.38 (*n* = 20)     98.26 ± 8.87 (*n* = 50)     Blister fluid
  Passi et al. \[[@B26]\]   U              92.32 ± 23.67 (*n* = 9)      182.58 ± 73.67 (*n* = 15)    115.01 ± 29.57 (*n* = 10)   Blister fluid

###### 

The level of glutathione peroxidase of segmental vitiligo patients, nonsegmental vitiligo patients, and healthy controls (mean ± SD).

  Study                         Unit           Case                       Control                      Source                       
  ----------------------------- -------------- -------------------------- ---------------------------- ---------------------------- -------
  Chen et al. \[[@B10]\]        U/L            141500 ± 9210 (*n* = 8)    138560 ± 14620 (*n* = 124)   216440 ± 8610 (*n* = 50)     Serum
  Ma et al. \[[@B11]\]          U/L            98.33 ± 20.34 (*n* = 23)   103.95 ± 18.73 (*n* = 46)    154.76 ± 27.06 (*n* = 44)    Serum
  Shajil and Begum \[[@B22]\]   U/mg protein   916.8 ± 183.3 (*n* = 30)   953.4 ± 151.9 (*n* = 94)     1036.8 ± 269.6 (*n* = 126)   Blood

###### 

Metaregression analyses of potential source of heterogeneity.

  Heterogeneity factors   Coefficient   Std. Err.   *z*     *p* \> \|*z*\|   95% CI      
  ----------------------- ------------- ----------- ------- ---------------- ----------- -----------
  Race                                                                                    
   Univariate             −1.940708     .6522389    −2.98   0.003            −3.219072   −.6623431
   Multivariate           −1.811697     .6340008    −2.86   0.004            −3.054315   −.569078
  Country                                                                                 
   Univariate             −.158666      .2952626    −0.54   0.591            −.73737     .420038
   Multivariate           −.3211        .27018      −1.19   0.235            −.8506431   .2084431
  Sample Source                                                                           
   Univariate             .3021601      .2049701    1.47    0.140            −.099574    .7038942
   Multivariate           .370906       .1947404    1.90    0.057            −.0107781   .7525901

*Note*. Std. Err., standard error; 95% CI, 95% confidence interval; UL, upper limit; LL, lower limit.
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